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The encounter between Mycobacterium tuberculosis (Mtb) and the host leads to
a complex and multifaceted immune response possibly resulting in latent infection,
tubercular disease or to the complete clearance of the pathogen. Macrophages and
CD4+ T lymphocytes, together with granuloma formation, are traditionally considered
the pillars of immune defense against Mtb and their role stands out clearly. However,
there is no component of the immune system that does not take part in the response to
this pathogen. On the other side, Mtb displays a complex artillery of immune-escaping
mechanisms capable of responding in an equally varied manner. In addition, the role of
each cellular line has become discussed and uncertain further than ever before. Each
defense mechanism is based on a subtle balance that, if altered, can lean to one side
to favor Mtb proliferation, resulting in disease progression and on the other to the host
tissue damage by the immune system itself. Through a brief and complete overview of
the role of each cell type involved in the Mtb response, we aimed to highlight the main
literature reviews and the most relevant studies in order to facilitate the approach to such
a complex and changeable topic. In conclusion, this narrative mini-review summarizes
the various immunologic mechanisms which modulate the individual ability to fight Mtb
infection taking in account the major host and pathogen determinants in the susceptibility
to tuberculosis.
Keywords: Mycobacterium tuberculosis, tuberculosis, children, immune response, immunity, macrophage,
adaptive immunity, granuloma
INTRODUCTION
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb) infection, was among the top
10 causes of death worldwide in 2017 with about 1.5 million registered deceases (1). Mtb was
responsible for approximately 10.0 million incident cases of TB disease with 10% of these occurring
among children (1). One to five bacilli may suffice to transmit the infection by air (2). When
inhaled, Mtb encounters a first line of defense consisting of airway epithelial cells (AECs) and
“professional” phagocytes (neutrophils, monocytes and dendritic cells) (3, 4). If this first line
succeeds in eliminating theMtb rapidly, the infection aborts (5). Otherwise, phagocytes are infected
and the Mtb reproduces inside the cells, initially causing few, if any, clinical manifestations (5).
The establishment of the infection, the development of active TB (ATB) rather than latent TB
infection (LTBI) and the eventual evolution of LTBI to ATB depends on the complex relation
between bacterial and host factors.
The aim of this narrative minireview is to give a hint of the complexity of the above-
mentioned determinants and to briefly summarize the major defense mechanisms of innate and
adaptive immunity against Mtb outlining the role of the different cell populations and their
complex interplay.
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METHODS
In order to perform a narrative review of the available literature,
we searched the PubMed database fromApril 2014 through April
2019, using the following key words: “immune,” “immunity,”
“tuberculosis,” “Mycobacterium tuberculosis.” Subsequently, for
each topic, specific key words (“susceptibility,” “resistance,”
“virulence,” “airway epithelial cell,” “macrophage,” “neutrophil,”
“dendritic cell,” “natural killer,” “mast cell,” “complement,”
“CD4,” “CD8,” “humoral,” “antibody,” and “granuloma”) were
associated with the word “tuberculosis” in order to access
proper specific literature. The search and the selection process
were not systematic. Articles were limited to English language
and full text availability, and they were excluded if they were
redundant or not pertinent. References of all relevant articles
were also evaluated, and studies published previously than
2014 were cited if considered relevant. Results were critically
summarized in the following paragraphs: (1) “host and bacterial
determinants in human tuberculosis,” (2) “innate immune
response against Mycobacterium tuberculosis,” and (3) “adaptive
immune response againstMycobacterium tuberculosis.”
HOST AND BACTERIAL DETERMINANTS
IN HUMAN TUBERCULOSIS
Several epidemiological models of family members who have
long shared the bedroom with subjects with ATB, sailors who
lived in confined spaces with subjects with open TB and extensive
case studies of South Africanminers andNorwegian or American
students, have clearly demonstrated that 5 to 20% of those
who meet subjects with ATB do not become infected (resilient
individuals or resisters), or become infected only transiently
and then get rid of the infection (early sterilization or early
clearance) (6). An individual can be defined resilient if after close
and prolonged contact with the index case shows simultaneous
negativity of the skin reactivity test and of the IFN-γ release assay
(IGRA) which persists for at least 1 year. Studies carried out on
siblings have shown that Mtb resilience is more frequent between
two siblings than between two unrelated subjects, suggesting
the role of genetics in the development of Mtb resilience (7).
Genome wide linkage analysis detected several loci like 2q21-
2q24, 5p13-5q22, and the TST1 on 11p14 associated with the
resilient phenotype (8, 9).
On the other side, the study of TB susceptibility, has shed
light onto various components of immunity to mycobacteria
in humans. Different genetic polymorphisms which modulate
the host immune response in favor of TB infection and
disease progression have been identified in human leukocyte
antigens (HLA), toll like receptors (TLR), vitamin D receptors
(VDR), cytokines with their receptors and many other
functional immune components (10, 11). Moreover, mendelian
susceptibilities to mycobacterial disease (MSMD) have been
identified as clinical conditions with selective susceptibility
to poorly virulent mycobacteria in the absence of patent
immunodeficiency (12). Since 1996, 11 genes which underlie
21 different genetic disorders related to interferon (IFN)-γ
immunity and responsible for MSMD have been identified (12).
Furthermore, transcriptomic studies have described a TB
signature of neutrophil-driven IFN-inducible genes in ATB,
including IFN-γ but also type I IFNs, reflecting disease
extension and response to treatment and highlighting the
previously under-appreciated role of IFNαβ signaling in TB
pathogenesis (4, 13, 14).
Beyond host factors, bacterial virulence constitutes the other
major player when evaluating the risk of TB infection. Virulence
is not merely limited to bacterial strain or burden in respiratory
secretion but takes into account the differential Mtb gene
expression in the different phases of infection. Mtb lacks
classical virulence factors such as toxins and its immune-
escaping ability depends on the modulation of lipid metabolism,
metal-transporter proteins, protease, proteins inhibiting the
antimicrobial effectors of macrophages (M8s) and many
others (15).
The study of immune response in resilient and susceptible
individuals, together with bacterial factors, has offered
fundamental information for the understanding of TB
immunology suggesting potential improvements in diagnostic
and therapeutic approaches (Table 1).
INNATE IMMUNE RESPONSE AGAINST
Mycobacterium tuberculosis
The significance of innate immunity in the defense against Mtb
stands out clearly as we consider the MSMD where a disruption
of the innate axis leads to dramatic, life-threatening clinical
presentation of TB (12).
M8, neutrophils, dendritic cells (DCs), natural killer cells
(NK), mast cells and complement are the major players of innate
immunity. On the other hand, AECs also contribute to the
defense attempt against Mtb and could be considered as innate
immunity components (Table 1).
Airway Epithelial Cells
AECs are the first cells to come in contact with Mtb. Beyond
their major role as physical barriers, they display several
immunological functions albeit being traditionally considered as
“non-professional” immune cells. Through pattern recognition
receptors (PRRs), AECs can perceive the presence of Mtb and
consequently modulate the composition of the airways surface
liquid improving its antimicrobial capacity (16). Moreover,
PRRs activation leads to the production of inflammatory
cytokines and to the activation of mucosal-associated invariant
T cells stimulating IFN-γ and tumor necrosis factor (TNF)-α
production (17).
Macrophages
M8s are the first line of defense, but only if the ratio of
forces lies clearly to their advantage and the intervention is
immediate they can cancel the infection (5, 18). Otherwise, they
favor its development because they become first a niche for
the slow replication of the Mtb and then the sanctuary for the
persistence of the infection inside the phagosome during the
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TABLE 1 | Key literature of the present review.
Paragraph Topic Major references
Host and bacterial
determinants in human
tuberculosis
Host Genetic
polymorphism
- Harishankar et al. (10)
- Casanova and Abel (7)
- Cobat et al. (8)
- Stein et al. (9)
- van Tong et al. (11)
MSMD - Rosain et al. (12)
Transcriptomic
studies
- Berry et al. (13)
- Blankley et al. (14)
Bacterial
Virulence factors
- Forrellad et al. (15)
Innate immune response
against Mycobacterium
tuberculosis
AECs - Li et al. (16)
- Harriff et al. (17)
Macrophages - Queval et al. (18)
- Lerner et al. (19)
- Yuk et al. (20)
- Gröschel et al. (21)
- Bustamante et al. (22)
- Sia et al. (23)
- Sun et al. (24)
- Neyrolles et al. (25)
- Botella et al. (26)
Neutrophils - Kroon et al. (27)
- Lowe et al. (28)
- Tan et al. (29)
- Zhang et al. (30)
Dendritic cells - Mihret (31)
- Khan et al. (32)
- Wu et al. (33)
- Balboa et al. (34)
- Georgieva et al. (35)
- Velasquez et al. (36)
- Ehlers (37)
NK cells - Esin and Batoni (38)
- Arora et al. (39)
- Zhang et al. (40)
Mast Cells - Garcia-Rodriguez et al. (41)
- Carlos et al. (42)
Complement - Lubbers et al. (43)
- Cai et al. (44)
Adaptive immune response
against Mycobacterium
tuberculosis
CD4+ T
lymphocytes
- Cooper (45)
- Sia et al. (46)
- Domingo-Gonzalez et al. (47)
- Parkash et al. (48)
- Sallin et al. (49)
CD8+ T
lymphocytes
- Lin and Flynn (50)
- Canaday et al. (51)
- Oddo et al. (52)
Humoral
immunity
- Kozakiewicz et al. (53)
- Jacobs et al. (54)
- Glatman-Freedman
and Casadevall (55)
- Lu et al. (56)
Granuloma - Ramakrishnan (57)
- Russell (58)
- Reece and Kaufmann (59)
- Refai et al. (60)
- Martinot (61)
- Russell et al. (62)
The major references are grouped basing on the different topics addressed in each
paragraph. The most relevant and comprehensive review or study for each topic is
highlighted in bold. MSMD, Mendelian Susceptibility to Mycobacterial Disease; AEC,
Airway Epithelial Cell; NK, Natural Killer cells.
latent infection phase. Mtb expresses an extremely wide variety of
virulence factors that counteract M8s efforts in suppressing the
pathogen. Among Mtb strategies we can include the inhibition
of intracellular trafficking, the inhibition of autophagy, the
acquisition of cytosol access, the induction of host cell death and
the neutralization of toxic components as reactive oxygen species
and toxic metals (19).
Whilst IFN-γ is a key element in the containment of Mtb
within the M8, it is now widely recognized that performing
this function requires the presence of vitamin D (63). Thanks to
vitamin D, the macrophage increases phagosomematuration and
the production of antimicrobial peptides through the maximal
regulation of the hCAP-18 gene encoding for cathelicidin
antimicrobial peptide which activates, in turn, the transcription
of autophagy-related genes (20). The 6 kDa early secretory
antigenic target (ESAT-6) protein family secretion (ESX) system
is a sophisticated secretion system that Mtb uses to export
proteins with immune-escaping activity. So that while the
IFN-γ axis is struggling against the ESX-system to enhance
phagolysosmal activity, vitamin D deficiency abets the Mtb
replication (21).
Nitric oxide (NO) within macrophages plays a less important
role in humans than that one observed in animal models (19).
Although, in humans too, reactive oxygen species (ROS) play
a well-documented role in the immune response to Mtb as
highlighted by the discovery of TB susceptibility in patients
displaying mutations in a catalytic subunit of NADPH-oxidase
2 involved in ROS production on phagolysosomal membrane
(22, 23). Moreover, it is demonstrated that Mtb affects NADPH-
oxidase activity through nucleoside diphosphate kinase (Npk)
interaction with small GTPases involved in NADPH-oxidase
assembly and functioning (24).
The fight unfolds inside the phagosome of the M8 between
the cell and the Mtb with metals as a battlefield of sorts (25). The
M8 delivers an overload of copper and zinc, which are toxic to
Mtb at high concentrations. Mtb deploys a series of protection
mechanisms that include controlling the capture of such metals,
oxidation, and an increase in efflux (25). The up-regulation of
ctpC gene encoding for the P-type ATPase which regulates the
intra-bacterial levels of Zinc is a clear example of how Mtb
manages to prevent heavy metal poisoning (26). As a counter-
move, the M8 then attempts to block the arrival of nutrients to
the Mtb such as iron and manganese (25).
Neutrophils
Neutrophil granulocytes are the most widely present cell
population within BAL and sputum in patients with active TB
(27). There is evidence of their role as defense mechanisms
against Mtb. In particular, there is a clear inverse correlation
between the number of neutrophilic granulocytes in the
peripheral blood and the hazard of developing TB after
contact with an infectious subject. Antimicrobial peptides and
apoptotic neutrophils are phagocytized by M8 and carry out
an effective activity against Mtb inside these cells (28). This is
possible thanks to the fusion, within the M8, of neutrophil
granules with phagosomes containing Mtb (29). Furthermore,
ETosis, extracellular traps (ET) formation, is a type of cell
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death that differently from apoptosis is characterized by DNA
release, consequent M8 activation and the formation of a
DNA scaffold that incorporates pathogens and exposes them
to antimicrobial molecules (64). The formation of neutrophils
ETs, thus constitutes an improved killing strategy and a synergic
alliance between phagocytes.
Moreover, as with many immune mechanisms, neutrophils
do not only play a positive role, but can eventually constitute
a negative element, causing tissue damage through production
and subsequent release of their antimicrobial products (27). To
this phenomenon, it must be added the potentially negative
interaction with lymphocytes. Neutrophils express on their cell
membrane the ligand 1 of cell death (programmed death ligand
1 or PD-L1), which interacts with the lymphocyte receptor
for programmed death (programmed death receptor or PD-1),
and determines, in the course of chronic infections, the loss of
function and finally the death of lymphocytes (30).
Neutrophils with expressed PD-L1 are present in high
proportion in patients with ATB.
Dendritic Cells
DCs are functionally located in the middle between innate
and adaptive immunity. These cells play a fundamental role in
the immune defense system due to antigen presentation, co-
stimulating activity and the large cytokine production capacity
with activity on the lymphocytes cluster of differentiation (CD) 4
(32). DCs role in TB immunity is controversial. Present evidence
is not sufficient to establish whether these cells strengthen
cellular immunity or if their manipulation by the Mtb can be
used as a tool to diminish specific T-cell response (31). DCs
soon become a niche for the Mtb. CD209, also called DC-
specific intercellular adhesion molecule 3-grabbing non-integrin
receptor (DC-SIGN), represents the gateway of Mtb into the
DC (31). CD209 is, under normal conditions, a receptor for
CD54, the intercellular adhesion molecule 1 (ICAM1) present
on endothelial cells where it favors DCs migration. CD209 is
coupled with the lipoarabinomannan mannose (ManLAM) of
the Mtb that penetrates into the cell. This penetration leads to
a disruption of DCs activity by prompting the production of
interleukin (IL)-10 and reducing the production of IL-12, thus
causing a suppression of T lymphocytes activity (33, 34). The
manipulation of the maturation of the DCs probably represents
one of the winning strategies of Mbt that, by restraining the
activity of DCs and, consequently, of T lymphocytes, allows
the Mtb, whose speed of growth is relatively slow, to efficiently
establish a bridgehead in the airways (35). Based on the above
mentioned mechanism DC-SIGN has recently been proposed
as a potential target for a vaccine purpose eventually able to
enhance immunity against Mtb (36). On the other side, DC-
SIGN may prevent tissue pathology by maintaining a balanced
inflammatory state and thus promoting host protection (37).
Natural Killer Cells
It is certain that NK cells enter the immunological circuit
of Mtb infection both in their CD56 diminished phenotype
(preferential cytotoxic activity) and in CD56 bright phenotype
(preferential cytokines secreting activity) (38). In several studies
the percentage representation of NK cell is augmented in the
peripheral blood of patients with ATB (65). There is a direct
relationship between NK cell representation, clinical condition
and response to therapy (38, 65). Nonetheless, it has not yet been
ascertained exactly what the cause and the consequence is (38).
Several components of theMbt wall are recognized and bound
by the NKp44 receptor of NK cells (39). In addition, Mtb-
infected NKs lyse and stimulate M8s to produce IFN-γ and IL-
22, which increase phagolysosomal fusion thus inhibiting Mtb
replication and stimulate the production of additional IFN-γ by
CD8+ lymphocytes. This effect is mediated by the IL-15 and IL-
18 production by an infected M8. As a further infection control
mechanism DCs favor the development of T lymphocytes with
γδ receptor through TNF-α and IL-12 production (40).
Mast Cells
The role of mast cells in Mtb infection is not well-known
in humans (41). In mice, mast cells capture Mtb via CD48
and internalize it. This process ensues the development of a
cytokine cascade, some of them with protective roles, including
IL-12, IL-13, IL-6, CXLL2, CCL7, CCL2, TNF-α, and consequent
neutrophils recall in the site of infection (41). Histamine’s
role is ambivalent in terms of Mtb clearance as on one hand
it augments lung neutrophilia but on the other it seems
to impair the efficient production of a T helper 1 (Th1)
response (42). The presence of mast cell ETs containing Mtb
in humans has not been proved. However, mast cells enclose
a large number of mediators known to take part in the
process (41).
Complement Proteins
The role of the complement cascade on the progression of the
infection and Mtb disease is almost unknown (44). It is likely
that the C5 and C7 components play a defensive role. However, it
has been observed that a high expression of C1q correlates with
a worse clinical condition, so as to be a marker between latent
TB and active TB but still with unclear significance in terms of
pathogenesis (43, 44).
ADAPTIVE IMMUNE RESPONSE AGAINST
Mycobacterium tuberculosis
The immune response of T lymphocytes begins at the moment
that Mtb spreads inside the lymph nodes but its arousal lays
in the early activation of the innate immune system. Inside the
lymph nodes, T lymphocytes undergo a process of activation
and expansion of the specific populations for the Mtb antigens.
However, at this point, the largest part is done and the
infection is now established. Cellular immune response can be
evidenced 2–6 weeks after Mtb infection by the development
of a delayed hypersensitivity response to intradermal injected
tuberculin (DHT) or purified protein derivative. It is important
to underline that protective response to TB does not relate
with DHT positivity and disease can occur in those who mount
adequate DHT response (66) (Table 1).
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Lymphocytes T CD4+
The in vivo human model of HIV-infected CD4+-depleted
patients is the most striking evidence of the pivotal role of
these cells in TB immunity. The process of maturation of the
phagosome of M8 is facilitated and increased by IFN-γ, the
production of which is mostly dependent on the T lymphocytes
CD4+ with a minor support of lymphocytes CD8+ and T
lymphocytes with γδ receptor (45). Animal models of knockout
mice for IFN-γ clearly show that these animals suffer a very
severe course of Mtb infection exactly as it happens in humans
with MSMD. It is well known that patients with mutations in
genes encoding IFN-γ or its receptors undergo disseminated
infection by BCG or other non-tuberculous components of the
mycobacteria genus (12). IFN-γ production is modest in patients
with active TB, but recovers with antitubercular treatment
without reaching levels similar to those of uninfected subjects.
The optimal production of IFN-γ, as well as that of IL-17 (67),
is linked to an equally optimal cooperation between DCs and
T lymphocytes CD4+. In its defensive strategy, Mtb markedly
interferes in the CD40-CD40 ligand binding, that is essential for
the cooperation between both cell lines (46). The importance of
IFN-γ production by CD4+ cells is particularly relevant at the
early stages of Mtb infection as it is demonstrated that adequate
IFN-γ levels can be obtained with 3 weeks of delay even in CD4-
disrupted mice thanks to the compensation offered by other cell
types like CD8+ (68).
Moreover, IFN-γ cannot control infection alone and it
requires the association of other molecules such as IL-6, IL-1 and
the TNF-α. The chemokines CCL5, CCL9, CXCL10, and CCL2
attract immunity cells at the site of infection and their production
is stimulated by TNF-α and boosts the production of NO by
M8 (47).
Several studies, both in adult and pediatric patients, have
demonstrated CD4+ percentage and absolute value reduction in
the peripheral blood of patients with ATB suggesting both an
augmented pooling in the site of infection but also eventually
a primary role of TB in immune modifications related with the
severity of infection (65).
A portion of T lymphocytes are Foxp3+ and perform a control
function over the activity of other T lymphocytes in fact, they
are defined as T regulators (Treg). It is only on a hypothetical
level that we can imagine any positive role of this cell line on
the disease progression limiting tissue damage by other immune
cells; however, it has been ascertained that, by restraining the
response of the T lymphocytes, the Tregs favor the infection
development and persistence (48). Similarly, T lymphocytes
CD4+ may deal more damage, or at least become irrelevant,
rather than hinder the progress of the infection (49).
Lymphocytes T CD8+
For a long time, it was considered that, unlike T lymphocytes
CD4+, T lymphocytes CD8+ had no role in controlling
the infection and Mtb disease. This concept stemmed from
the modest availability of human models with T lymphocyte
CD8+ defect, unlike the large human model of HIV infection.
An activity against Mtb is conceivable considering that T
lymphocytes CD8+ recognize Mtb antigens through class I
molecules of the major histocompatibility complex (MHC), and
produce IL-2, IFN-γ and TNF-α, which have a well-known role
in controlling Mtb. Furthermore, T lymphocytes CD8+ exert a
cytolytic action against Mtb by means of perforin and granulysin,
albeit not by Fas (CD95) -Fas ligand (50, 51) interaction. This
direct cell-to-cell contact determines the apoptosis of the Mtb-
infected cell (especially M8) depriving Mtb from its natural
growth environment and at the same time reducing its viability
by unknown mechanism (52). On the other hand, lymphocytes
CD8+ produce IL-10 and TGF-β which instead favor the
development of the Mtb infection.
Humoral Adaptive Immunity
The role of humoral adaptive immunity in TB is extremely
uncertain (53, 54). Complement-mediated opsonization does not
alter Mtb survival. High levels of antibody titers correlate with
more serious conditions of infection and disease, and passive
immunization with antibodies does not confer protection (55).
Patients with a defective antibody-productionmechanism and/or
B lymphocyte defect are not particularly at risk of TB infection.
The role of the crystallizable fragment or Fc in the constant
portion of the immunoglobulin, which binds and activates
various cell lines present in the granuloma (NK cells, monocytes,
neutrophils) the low-affinity FcγRIIIb receptor and the high
affinity FcγRIIa receptor have shown different functional profiles
and glycosylation patterns in subjects with ATB rather than
LTBI (54, 56).
The loss of FcγRIIIb activity and the increase of FcγRIIa-
mediated inhibitory function (which correlates with a high IL10
production) are associated with a worse clinical profile and can
distinguish ATB from LTBI and suggests a role of antibodies
in the augmented phagolysosomal maturation and Mtb killing
observed in LTBI patients (56).
The Ancestral Defense: Granuloma
Following the development of adaptive immunity, a complex
and well-coordinated mechanism is established between both
immunity mechanisms, i.e., innate and adaptive, which seal the
Mtb inside granulomas (5, 58, 59). This mechanism develops
in at least 90% of the infected subjects and leads to LTBI.
During latent TB, which would be better described as non-
replicating-persistence phase (in fact, Mtb works perfectly albeit
in a different way than during active TB), the subject is generally
positive for the tuberculin skin test and for the IGRA (69).
Latent TB becomes active when, for the most various reasons,
a condition of immunodepression develops. At this stage, the
subject may become capable of transmitting the infection because
the granuloma opens in the bronchial lumen and Mtb are
expelled when coughing. At the beginning of the infection, Mtb
demands an environment with inflammatory traits to develop
the granuloma; subsequently, however, its survival is linked to
an environment lacking or with low inflammation. This switch
is caused by ESAT-6 (60), a well-known Mtb virulence factor
involved in the ESX secretion system, to which it gives its
name. ESAT-6 causes the transformation of M8 from phenotype
M1, which produces IL-6, IL-12 and TNF-α, into M8 with
phenotype M2, which is capable of stimulating production of
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IL-10 (60, 61, 70). As currently known, IL-6 and TNF-α favor
inflammation, whilst IL-10 curbs it. Accordingly, the formation
of the granuloma is triggered by the M8 and then develops
with multi-nucleated giant cells andM8with abundant presence
of intracytoplasmic lipids, which lend these cells their frothy
appearance. Around these cells, there is a ring of T lymphocytes
although B lymphocytes, neutrophils and dendritic cells (CD)
also participate in the formation of granuloma (4).
Inside the granuloma, cholesterol—and not glucose or
glycerol—is the only carbon source. This leads to a lack of carbon
and nutrients, hypoxia and a high concentration of nitric oxide
(NO). The significance of cholesterol in the survival ofMtb inside
the granuloma is evidenced by the negative role that statins play
against Mtb (61, 70).
The debate remains open on whether the granuloma is purely
protective for the host or if it promotes disease progression
and tissue damage (4). This uncertainty depends on the
extreme heterogeneity detected in granuloma morphology at the
different stages of disease, on the role of inflammation, hypoxia
and differential Mtb gene expression and lipid metabolism
manipulation inside the granulomas of ATB and LTBI patients
(62). The most likely answer is that an homeostatic interaction
establishes and the granuloma becomes a well-suited shelter for
both Mtb long-term survival and host protection (57).
DISCUSSION
Mycobacterium tuberculosis: The Great
Manipulator
The different cell lines of innate and adaptive immunity come
into play at different times in the battle against Mtb in a clash
in which the genetic susceptibility of the host and the virulence
of the pathogen play decisive roles for the final outcome. The
success of Mtb over thousands of years against man arises
from its extraordinary ability to subvert the mechanisms that
should eliminate it in the M8 from the infection onset. At the
onset of the infection, Mtb manages to perforate the phagosome
in the M8 through the ESX system and, therefore, to block
its maturation via Npk, which inhibits lysosomal traffic and
NADPH-oxidase activity (31). With various mechanisms, some
of which also operate at the level of macrophage DNA, the Mbt
prevents the activation of pathogen destruction systems, which
are implemented through autophagy. The Mtb DNA manages to
prevent the activation of the AIM2 inflammasome thus hindering
the synthesis of IL-1β and IL-18 (31). Under normal conditions,
IFN-γ stimulates the expression of MHC class II molecules
on the M8. But Mtb, thanks to the prolonged activation of
TLR2, succeeds in suppressing this mechanism. Even in cells that
already express class II MHC molecules, Mtb manages to block
the presentation of antigens by the action on ESCRT (endosomal
sorting complexes required for transport) of its EsxG·EsxH
protein (31). The “great manipulator” also interferes with the
functions of DCs, neutrophils and all other components of the
immune system.
In conclusion, having to deal with a micro-organism of great
evasive abilities, immune mechanisms have only one way to go:
to focus on a very rapid response at the onset of the infection.
Paraphrasing a famous aphorism by General Erwin Rommel
about amphibious battles that is well-suited to TB, victory
or defeat against Mtb is decided in the first moments
of the infection (5). Exactly as it happened on the first
day of the amphibious assault, the day that General Erwin
Rommel defined as “the longest day.” When it comes to
implementing new prevention and therapeutic approaches, a
clear understanding of the interplay between the immune system
and Mtb at a molecular level is the only way to unravel this
millenary skein.
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